Saltar al contenido

Home
Sobre nosotros
Oncología
Servicios preclínicos
Accionistas
Noticias y recursos
Contáctenos
Español

Menú

Home
Sobre nosotros
Oncología
Servicios preclínicos
Accionistas
Noticias y recursos
Contáctenos
Español

Anuncios

Inversores

Reportes
financieros

Informes de
analistas

Comunicados
de prensa

Accionistas

Inversores

Reportes financieros

Informes de analistas

Comunicados de prensa

Accionistas

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

septiembre 23, 2024

Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology

marzo 5, 2024

Operational Updates – February 2024

febrero 7, 2024

Operational Updates – October 2023

noviembre 9, 2023

Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

agosto 18, 2023

Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening

julio 13, 2023

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

julio 27, 2022

Operational Updates and Management Accounts

febrero 18, 2022

Quarterly Updates – March 2021

mayo 3, 2021

Delisting from ASX Official List

febrero 26, 2021

Appendix 4C – quarterly

febrero 1, 2021

4C Commentaries and Management Updates

mayo 1, 2020

Appendix 4C – quarterly

abril 30, 2020

Board Changes – 3 Mar 2020

marzo 3, 2020

Invitrocue enters MOU to establish a Joint Venture for Brazilian and Latin American Market

febrero 11, 2020

Appendix 4C – Commentaries & Management Updates

febrero 6, 2020

Quarterly Appendix 4C – December 2019

enero 1, 2020

Cleansing prospectus

diciembre 17, 2019

Change of Director's Interest Notice – Dr Andreas Lindner

diciembre 17, 2019

Proposed issue of Securities – IVQ

diciembre 17, 2019

Significant investment and joint venture with a fund

diciembre 9, 2019

Results of Annual General Meeting – 2019

noviembre 28, 2019

Quarterly Appendix 4C

noviembre 1, 2019

Notice of Annual General Meeting – 2019

octubre 30, 2019

Appendix 4E – 2019

octubre 21, 2019

Invitrocue Establishes Hong Kong Laboratory

octubre 21, 2019

Invitrocue Clinical Studies underway in Germany

octubre 21, 2019

Annual Report – 2019

octubre 3, 2019

Appendix 3B – September 2019

septiembre 9, 2019

Collaboration with National University Hospital Singapore

septiembre 9, 2019

Quarterly Appendix 4C and Business updates

septiembre 9, 2019

Invitrocue Appoints Global Insurance Advisor

mayo 6, 2019

Quarterly Appendix 4C and Business updates

abril 30, 2019

Appendix 3B – March 2019

abril 30, 2019

Cleansing Statement – April 2019

abril 30, 2019

Appendix 3Z – Jamie Khoo – March 2019

marzo 15, 2019

Appendix 3X – Kit Wei Lui – March 2019

marzo 15, 2019

Board Changes – March 2019

marzo 12, 2019

Cleansing Statement – March 2019

marzo 6, 2019

Appendix 3B – March 2019

marzo 6, 2019

Appendix 4D – Half Yearly Report and Accounts

marzo 4, 2019

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

febrero 19, 2019

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

febrero 11, 2019

Quarterly Appendix 4C and Business updates

febrero 1, 2019

IVQ technology development agreement with SIBCB on breast cancer.

enero 23, 2019

Invitrocue roll-out of Onco-PDO services in Germany

enero 21, 2019

Invitrocue Appoints Renowned Oncology Researcher Professor Jesús García-Foncillas as Clinical Advisor

enero 15, 2019

Expiry of unlisted options – Jan 2019

enero 15, 2019

Final Director's Interest Notice

enero 11, 2019

Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor

enero 11, 2019

Invitrocue announced Board Changes

enero 9, 2019

Change of Director's Interest Notice

diciembre 27, 2018

Change of Director's Interest Notice

diciembre 21, 2018

Change of Director's Interest Notice

diciembre 19, 2018

Change of Director's Interest Notice

diciembre 18, 2018

Change of Director's Interest Notice

diciembre 18, 2018

Change of Director's Interest Notice

diciembre 18, 2018

Appendix 3B – December 2018

diciembre 17, 2018

Cleansing Statement – December 2018

diciembre 17, 2018

Results of Annual General Meeting

noviembre 30, 2018

Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor

noviembre 19, 2018

Quarterly Appendix 4C and Business updates

noviembre 1, 2018

Notice of Annual General Meeting/Proxy Form

octubre 30, 2018

Initial Director's Interest Notice – Dr Gary W Pace

octubre 23, 2018

Appointment of Dr. Gary W. Pace as director

octubre 23, 2018

Assoc Prof Iyer as Chair of IVQ Medical Advisory Board

octubre 22, 2018

Annual Report to shareholders

septiembre 28, 2018

Appendix 4G

septiembre 28, 2018

Notice of Ceasing to be a Substantial Holder

septiembre 10, 2018

Business updates

septiembre 4, 2018

Preliminary Final Report

agosto 31, 2018

Change in substantial holding

agosto 28, 2018

Appendix 4C – quarterly

julio 31, 2018

Expiry of Unlisted Warrants

julio 17, 2018

Expiry of Unlisted Warrants

julio 2, 2018

Cleansing statement

junio 28, 2018

Appendix 3B

junio 28, 2018

Proposed issue of securities

junio 26, 2018

Change in substantial holding

mayo 25, 2018

Appendix 4C – quarterly

abril 30, 2018

Appendix 4G

abril 27, 2018

IVQ launches Personalised Cancer Screening Service Onco-PDO

abril 13, 2018

Half Yearly Report and Accounts

febrero 28, 2018

Grant from Northern Ireland to commercialize Onco-PDO

febrero 26, 2018

Investor Presentation

febrero 23, 2018

Change of Director's Interest Notice – Jamie Khoo

febrero 20, 2018

Change of Director's Interest Notice – Steven Fang

febrero 20, 2018

Change of Director's Interest Notice

febrero 14, 2018

Change of Director's Interest Notice

febrero 14, 2018

Change of Director's Interest Notice

febrero 14, 2018

Change of Director's Interest Notice

febrero 14, 2018

Change of Director's Interest Notice

febrero 14, 2018

Initial Director's Interest Notice

febrero 12, 2018

Appendix 3B

febrero 9, 2018

Appointment of non-executive director

febrero 7, 2018

Appendix 4C & quarterly business update

enero 31, 2018

Appendix 3B

enero 29, 2018

IVQ successfully grows liver cancer organoids

enero 18, 2018

Escrow Release

enero 15, 2018

Cleansing Statement

diciembre 8, 2017

Appendix 3B

diciembre 8, 2017

Proposed Issue of Securities

diciembre 7, 2017

Results of Annual General Meeting

noviembre 30, 2017

2017 AGM Presentation

noviembre 30, 2017

Cleansing Statement

noviembre 13, 2017

Appendix 3B

noviembre 13, 2017

Proposed issue of securities

noviembre 10, 2017

Quarterly Business Update and Investor Calls

octubre 31, 2017

Appendix 4C – Quarterly Report

octubre 30, 2017

Notice of Annual General Meeting/Proxy Form

octubre 30, 2017

Annual Report to Shareholders

septiembre 29, 2017

Appointments to the Management Team

septiembre 28, 2017

Preliminary Final Report

agosto 31, 2017

IVQ receives award from Singapore government IP office

agosto 29, 2017

Investor Presentation

agosto 29, 2017

Appendix 4C – Quarterly Report and Business Update

julio 31, 2017

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

julio 24, 2017

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

julio 3, 2017

Cleansing Statement

junio 30, 2017

Appendix 3B – New Issue Announcement

junio 30, 2017

Proposed Issue of Securities

junio 29, 2017

Corporate Governance Statement

mayo 26, 2017

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

mayo 22, 2017

Response to ASX Appendix 4C Query

mayo 11, 2017

Appendix 4C – Quarterly Report

abril 28, 2017

Appendix 4D – Half Yearly Report and Accounts

febrero 28, 2017

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

febrero 23, 2017

Appendix 4C – Quarterly Report

enero 30, 2017

Escrow Release

enero 3, 2017

Results of Annual General Meeting 2016

noviembre 30, 2016

Invitrocue Appoints DasGupta Ramanuj, Ph.D as Senior Scientific Director

noviembre 24, 2016

Appendix 4C – Quarterly Report

octubre 31, 2016

Annual General Meeting 2016

octubre 28, 2016

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

octubre 24, 2016

Annual Report For The Period Ended 30 June 2016

septiembre 30, 2016

Addendum To Appendix 4E

septiembre 8, 2016

InvitroCue Awarded A*STAR Tender

septiembre 6, 2016

Preliminary Final Report

agosto 31, 2016

Appendix 3B – New Issue Announcement

agosto 30, 2016

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

agosto 22, 2016

Escrow Release

agosto 16, 2016

InvitroCue Announces New Program Focused on Hepatitis B Virus

julio 28, 2016

Appendix 4C – Quarterly Report

julio 28, 2016

Investment Fact Sheet July 2016

julio 11, 2016

InvitroCue Commences Pancreatic Toxicity Assay Development

julio 11, 2016

Notification of Change of Auditor

julio 7, 2016

Investor Presentation (Mandarin)

junio 14, 2016

Investor Presentation 16 May 2016

mayo 16, 2016

InvitroCue Announces Malaria Initiative

mayo 16, 2016

InvitroCue Expands 3D Cell-based Platform for Oncology

mayo 12, 2016

Appendix 4C – Quarterly Report

abril 27, 2016

InvitroCue and SciKon Innovation Forge an Alliance to Create the Future of Perfused Human Liver Tissue

abril 8, 2016

InvitroCue Launches Cellacyl: Proprietary Acyl Glucuronide Detection Assay

abril 8, 2016

New Issue Announcement

marzo 30, 2016

Initial Director's Interest Notice

marzo 24, 2016

New Issue Announcement

marzo 23, 2016

Becoming a Substantial Holder – Steven Fang

marzo 15, 2016

Agreement with London School of Hygiene & Tropical Medicine

marzo 9, 2016

Novel 3D in vitro Techniques for Modeling leishmaniasis

marzo 9, 2016

Operations Update

marzo 8, 2016

InvitroCue Expands Cell-based Lab in Suzhou to Meet Client’s Increase China Focus

marzo 5, 2016

Half Yearly Report

febrero 29, 2016

Investor Presentation

febrero 15, 2016

Operations Update

febrero 8, 2016

Becoming a Substantial Holder – Clearbridge Accelerator

febrero 2, 2016

ImageIQ And InvitroCue Forge Partnership To Advance Quantitative Image Analysis For Preclinical Researchers In Asia

febrero 1, 2016

NCCS And InvitroCue To Develop Quantitative Cancer Imaging And Radiomics Applications For Treatment Of Liver Cancer Patients

enero 28, 2016

Market Release: Reinstatement To Official Quotation

enero 22, 2016

InvitroCue and Swiss InSphero MOU Signing Ceremony

abril 8, 2015

PONERSE EN CONTACTO

Paseo Recoletos, 3
Planta 5a
28004 Madrid

+34 935 460 119

contact.es@invitrocue.com

SAC - SINGLAS Accredited Laboratory

Servicios

Home
Sobre nosotros
Oncología
Servicios preclínicos
Accionistas
Noticias y recursos
Contáctenos

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. Todos los derechos reservados
Impressum | Política de privacidad | Política de cookies | Configuración de cookies